Introduction
============

As a common head and neck cancer, nasopharyngeal carcinomas are generally either keratinizing or nonkeratinizing squamous cell carcinomas. Primary nasopharyngeal adenocarcinomas (NPACs) are rare neoplasms, constituting only 0.38% to 0.48% of all malignant nasopharyngeal neoplasms \[[@b1-crt-2016-195],[@b2-crt-2016-195]\]. Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA) is a small minority of conventional nasopharyngeal adenocarcinoma that exhibits papillary growth and abnormal expression of thyroid transcription factor 1 (TTF-1). To the best of our knowledge, only thirteen cases have been reported in the English-language literature and eleven in the Chinese-language literature to date ([Table 1](#t1-crt-2016-195){ref-type="table"}). In this article, we present a case of primary TL-LGNPPA and an analysis of its clinicopathological features.

Materials and Methods
=====================

A 15-year-old Chinese girl presented with a complaint of rhinorrhoea and nasal congestion with a duration of 1 month. On clinical examination, no thyroid tumor or other physical abnormalities were found. Nasal endoscopy identified a pedunculated polypoid mass with smooth surface that measured approximately 2.5×2 cm arising from the posterior nasal septum ([Fig. 1](#f1-crt-2016-195){ref-type="fig"}). A biopsy of the dominant portion of the mass was performed. Pathological analysis revealed an adenocarcinoma with papillary structure. Therefore, complete excision of the tumor was performed through an endoscope. Follow-up data showed no signs of local recurrence at up to 2 years after complete surgical removal.

The tissue was fixed in formalin and embedded in paraffin, after which 4-μm thin sections were cut and stained with hematoxylin and eosin. Immunohistochemical staining was performed using commercially available antibodies to the following antigens: pan-cytokeratin (CKpan), epithelial membrane antigen (EMA), vimentin, cytokeratin (CK) 7, CD15, thyroid transcription factor 1 (TTF-1), Ki-67, P40, S100, glial fibrillary acidic protein (GFAP), CK20, CDX-2, and thyroglobulin. At the same time, *in situ* hybridization for the presence of small Epstein-Barr virus (EBV)--encoded RNA was performed to identify the association between this tumor and EBV. All protocols were employed according to the manufacturers' recommendations ([Table 2](#t2-crt-2016-195){ref-type="table"}).

Results
=======

Histological examination of the biopsy specimen revealed a tumor that showed papillary configuration with hyalinized fibrovascular cores, similar to thyroid papillary carcinoma ([Fig. 2A](#f2-crt-2016-195){ref-type="fig"} and [B](#f2-crt-2016-195){ref-type="fig"}). The papillae were complex and tightly packed, and most were lined with cuboidal or columnar epithelia containing overlapping round to ovoid nuclei that displayed fine chromatin and mildly eosinophilic cytoplasm ([Fig. 2C](#f2-crt-2016-195){ref-type="fig"}). Only minor degrees of pleomorphism and hyperchromatism were observed. Small intra-nuclear cytoplasmic inclusions were present focally, although neither nuclear grooving nor ground glass nuclei were found. In small parts of the tumor, psammoma bodies were exhibited ([Fig. 2C](#f2-crt-2016-195){ref-type="fig"}). No necrosis or mitotic activity was discerned and no continuity between the tumor epithelia and normal nasopharyngeal mucosa or mucous glands was identified.

Immunoperoxidase studies showed that neoplastic cells were positive for CK7, vimentin, TTF-1, CKpan, and EMA ([Fig. 2D](#f2-crt-2016-195){ref-type="fig"}-[F](#f2-crt-2016-195){ref-type="fig"}). There was no immunoreactivity for thyroglobulin, CD15, S100, P40, CK20, CDX-2, and GFAP. In the most concentrated spot, the Ki-67--labeling index reached 5%. Negative results were revealed by *in situ* hybridization investigation of EBV.

Discussion
==========

NPAC contains two subtypes: conventional/surface origin-type and salivary gland-type. The former often originates from nasopharyngeal surface mucosa and presents with papillary configuration. The latter includes polymorphous low-grade adenocarcinoma, mucoepidermoid adenocarcinoma, and adenoid cystic carcinoma \[[@b12-crt-2016-195]\]. In 1988, Wenig et al. \[[@b20-crt-2016-195]\] first described thyroid-like papillary adenocarcinoma of the nasopharynx and proposed that these papillary adenocarcinomas should been regarded as a distinct entity from conventional adenocarcinomas in this region based on their indolent clinical behavior and low-grade histological features. Nasopharyngeal papillary adenocarcinoma (NPPA) was enrolled in the World Health Organization classification system of malignant epithelial tumors of the nasopharynx in 2005 \[[@b21-crt-2016-195]\].

Papillary configuration and aberrant TTF-1 expression are the distinguishing features of TL-LGNPPA, mimicking papillary thyroid carcinoma (PTC). TL-LGNPPA is an extremely rare neoplasm. To the best of our knowledge, few cases have been reported \[[@b3-crt-2016-195]-[@b19-crt-2016-195]\]. Clinical features of the published cases are listed in [Table 1](#t1-crt-2016-195){ref-type="table"}. The median age is 35 years in patients, ranging from 9 to 68 years. No difference was observed between the ratio of males to females. Instances of TL-LGNPPA were usually localized in the roof of the nasopharynx and posterior edge of the nasal septum. The excellent prognosis was obvious, with local excision being performed in all reported cases, and no local recurrence or metastasis reported.

Histologically, these neoplasms frequently exhibit papillary architecture lined by moderately pleomorphic columnar epithelial cells with fibrovascular cores, overlapping nuclei with clear optically chromatin, and psammoma bodies. These features are generally ascribed to PTC as well. However, the biphasic pattern of low-grade NPPA with a spindle cell component has been described in three case reports \[[@b7-crt-2016-195],[@b9-crt-2016-195],[@b12-crt-2016-195]\]. In this case, no obvious spindle cell component was observed. The biphasic pattern of TL-LGNPPA should be further investigated if a large number of cases can be collected.

Immunohistochemically, the positive expression of TTF-1 was the most characteristic feature of TL-LGNPPA. As a homeodomain containing transcription factor coded by NKX2-1, TTF-1 is usually found in lung, thyroid, and central nervous system tissue \[[@b22-crt-2016-195],[@b23-crt-2016-195]\]. Nevertheless, the positive expression of TTF-1 was also observed in other organs, including endometrium, colon, and breast \[[@b24-crt-2016-195]\]. Although the etiology of TTF-1 positive staining in TL-LGNPPA is still not clear, three mechanisms to explain this phenomenon were proposed in a recent case report. First, TL-LGNPPA may develop from ectopic thyroid tissue. Second, a gene rearrangement that affects TTF-1/NKX2-1 may result in abnormal expression of TTF-1. Finally, genetic instability and reprogramming of the cancer cells can cause dis-differentiation and lead to deregulation of TTF-1/NKX2-1 \[[@b12-crt-2016-195]\]. However, these presumptions are poorly evidenced owing to the extreme rarity of this tumor at the present time.

There are limited options available for differential diagnosis of papillary lesions in the nasopharynx. Because TL-LGNPPA display a striking resemblance to PTC, it is important to exclude nasopharyngeal metastasis from papillary adenocarcinoma of the thyroid gland for accurate diagnosis, treatment, and prognosis of the patient. Immunostaining for thyroglobulin and CD15 are critical and highly recommended to distinguish these two entities \[[@b25-crt-2016-195]\]. However, a case of TL-LGNPPA with focal expression of thyroglobulin was recently reported \[[@b11-crt-2016-195]\]. Polymorphous low-grade papillary adenocarcinoma (PLGA) is more aggressive and positive for vimentin and S100-protein. To date, positivity for TTF-1 has never been reported in PLGA \[[@b12-crt-2016-195]\]. Papillary variants of the intestinal type of adenocarcinoma (ITAC) show more nuclear atypia and commonly display mucinous differentiation. Moreover, these are often positive for CK20 and CDX2 \[[@b26-crt-2016-195]\]. Acinic cell carcinomas (ACC) with a papillary component are frequently cystic and variably positive for S100-protein and vimentin according to the range of differentiation (acinar to intercalated ducts) \[[@b9-crt-2016-195]\]. Extraventricular choroid plexus papillomas (CPP) at unusual localization must be taken into consideration, most of them was positive for S100 and negative for EMA, part of them was positive for GFAP. In our report, negative staining for thyroglobulin, CD15, S100, GFAP, CK20, and CDX-2 was revealed; therefore, PTC, PLGA, ITAC, ACC, and CPP should not be considered for accurate diagnosis.

It has been well documented that tumors originating from the nasopharyngeal epithelium were associated with the EBV. Investigation of *in situ* hybridization for EBV revealed negative results, which is concordant with reports by Wu et al. \[[@b4-crt-2016-195]\] and Fu et al. \[[@b5-crt-2016-195]\]. A close relationship between TL-LGNPPA and EBV was not confirmed; however, further investigation is needed because of the rarity of this neoplasm.

To date, no case of lymphatic metastasis or recurrence has been reported, indicating excellent prognosis for patients with thyroid-like papillary adenocarcinoma \[[@b8-crt-2016-195]\]. Generally, surgical excision is adequate for the treatment of TL-LGNPPA \[[@b20-crt-2016-195]\]. When surgical excision is not feasible or positive surgical margins have been observed, radiotherapy can be employed as an adjuvant treatment \[[@b20-crt-2016-195],[@b27-crt-2016-195]\].

Conclusion
==========

In conclusion, we present here a novel case of TL-LGNPPA with a review of its main clinicopathological features. Due to the rarity of this neoplasm and favorable clinical outcome, clinicians should pay more attention to accurate diagnosis of this entity, as well as its treatment and clinical prognosis.
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![Nasal endoscopy shows a pedunculated polypoid mass originating in the posterior nasal septum.](crt-2016-195f1){#f1-crt-2016-195}

![(A) The tumor displayed papillary structures with hyalinized fibrovascular cores (H&E staining, ×100). (B) Most papillae were lined with cuboidal or columnar epithelia (H&E staining, ×200). (C) Overlapping round to ovoid nuclei that displayed fine chromatin and psammoma bodies were exhibited (H&E staining, ×400). (D) Strong positive staining of cytokeratin 7 was displayed (immunohistochemical \[IHC\] staining, ×200). (E) Nuclear staining for thyroid transcription factor 1 was shown (IHC staining, ×200). (F) Positivity of vimentin was evident (IHC staining, ×200).](crt-2016-195f2){#f2-crt-2016-195}

###### 

Clinical summary of reported thyroid-like low-grade nasopharyngeal papillary adenocarcinoma

  No.   Source                                    Age (yr)   Sex   Location                                           Size (cm)     Macroscopic appearance                           Follow-up       Recurrence
  ----- ----------------------------------------- ---------- ----- -------------------------------------------------- ------------- ------------------------------------------------ --------------- ------------
  1     Carrizo and Luna \[[@b3-crt-2016-195]\]   9          M     Right nasopharyngeal wall                          2.0           Submucosal mass                                  2 yr            N
  2     Carrizo and Luna \[[@b3-crt-2016-195]\]   13         M     Roof of the nasopharynx                            1.5           NA                                               15 yr           N
  3     Wu et al. \[[@b4-crt-2016-195]\]          36         F     Left nasopharynx                                   1             Pedunculated polypoid mass                       3 yr            N
  4     Fu et al. \[[@b5-crt-2016-195]\]          68         M     Roof of the nasopharynx                            NA            Pedunculated tumor                               1 yr            N
  5     Bansal et al. \[[@b6-crt-2016-195]\]      32         M     Posterior end of the left nasal septum             NA            Pedunculated well-circumscribed lesion           2 yr            N
  6     Ohe et al. \[[@b7-crt-2016-195]\]         25         M     Roof of the pharynx                                0.8           Pedunculated mass                                13 mo           N
  7     Ohe et al. \[[@b7-crt-2016-195]\]         41         M     Posterior roof of the nasopharynx                  0.5           Pedunculated mass                                9 mo            N
  8     Sillings et al. \[[@b8-crt-2016-195]\]    19         M     Posterior superior free edge of the nasal septum   1.5           Pedunculated mass                                NA              N
  9     Petersson et al. \[[@b9-crt-2016-195]\]   39         F     Posterior edge of bony septum                      1             Polypoid mass                                    NA              N
  10    Huang et al. \[[@b10-crt-2016-195]\]      36         F     Roof of the nasopharynx                            NA            Pedunculated tumor                               31 mo           N
  11    Ozer et al. \[[@b11-crt-2016-195]\]       17         F     Posterior nasopharyngeal wall                      2.7×2.2       Bilobulated mass                                 1 yr            N
  12    Oishi et al. \[[@b12-crt-2016-195]\]      47         F     Posterior edge of the left nasal septum            2             Pedunculated mass                                19 mo           N
  13    Ozturk et al. \[[@b13-crt-2016-195]\]     24         F     Posterior septum                                   3.0×2.5       Polypoid mass                                    4 yr            N
  14    Wu and Liu \[[@b14-crt-2016-195]\]        31         M     Posterior of the nasopharynx                       0.6×0.5×0.6   Polypoid mass                                    9 yr and 8 mo   N
  15    Wu and Liu \[[@b14-crt-2016-195]\]        49         M     Pharyngeal recess of the nasopharynx               1.5×1         NA                                               4 yr and 7 mo   N
  16    Wu and Liu \[[@b14-crt-2016-195]\]        62         M     Posterior nasal septum                             0.5×0.5×0.3   NA                                               1 yr and 4 mo   N
  17    Wu and Liu \[[@b14-crt-2016-195]\]        42         F     Roof of the nasopharynx                            1×1×0.5       NA                                               7 mo            N
  18    Wu and Liu \[[@b14-crt-2016-195]\]        51         M     Posterior nasal septum                             1×1×0.8       Pedunculated papillary mass                      1 mo            N
  19    Zhang et al. \[[@b15-crt-2016-195]\]      57         F     Nasopharynx                                        2×1.5×1.5     Papillary mass                                   9 mo            N
  20    Kang et al. \[[@b16-crt-2016-195]\]       25         M     Nasopharynx                                        NA            Polypoid mass                                    1 yr            N
  21    Kang et al. \[[@b16-crt-2016-195]\]       36         M     Posterior nasal septum                             0.8×0.8×0.8   Polypoid mass                                    18 mo           N
  22    Li et al. \[[@b17-crt-2016-195]\]         26         F     Roof of the nasopharynx                            1.5×1.3×0.4   Polypoid mass                                    8 mo            N
  23    Han et al. \[[@b18-crt-2016-195]\]        40         F     Roof of the right posterior nasopharynx            2×1           Pedunculated polypoid mass                       1 yr            N
  24    Chen et al. \[[@b19-crt-2016-195]\]       42         F     Roof of the nasopharynx                            0.5×0.5       Polypoid mass                                    1 yr            N
  25    Present case                              15         F     Posterior nasal septum                             2.5×2         Pedunculated polypoid mass with smooth surface   24 mo           N

M, male; N, no; NA, not acquired; F, female.

###### 

Summary of primary antibodies and results of immunohistochemistry

  Antibody        Source                                     Dilution   Result
  --------------- ------------------------------------------ ---------- ----------------------------------
  CK              Ascend Bio, Guangzhou, China               1:100      \+
  EMA             Ascend Bio, Guangzhou, China               1:100      \+
  Vim             Ascend Bio, Guangzhou, China               1:100      \+
  CK7             Ascend Bio, Guangzhou, China               1:100      \+
  CD15            Ascend Bio, Guangzhou, China               1:200      --
  TTF-1           Ascend Bio, Guangzhou, China               1:400      \+
  Ki-67           Ascend Bio, Guangzhou, China               1:200      5% in the most concentrated spot
  P40             ZSGB Bio, Beijing, China                   1:200      \-
  S-100           Dako, Glostrup, Denmark                    1:3,200    \-
  GFAP            Dako, Glostrup, Denmark                    1:1,600    \-
  CK20            Ascend Bio, Guangzhou, China               1:200      \-
  CDX2            Ascend Bio, Guangzhou, China               1:400      \-
  Thyroglobulin   Ascend Bio, Guangzhou, China               1:800      \-
  EBER            Triplex International Bio, Fuzhou, China   RTU        \-

CK, cytokeratin; EMA, epithelial membrane antigen; Vim, vimentin; TTF-1, thyroid transcription factor-1; GFAP, glial fibrillary acidic protein; CK, cytokeratin; EBER, Epstein-Barr virus--encoded RNA; RTU, ready to use.
